Portal de Periódicos da CAPES

Kinetic Concepts in the Treatment of Breast Cancer

1993; Wiley; Volume: 698; Issue: 1 Linguagem: Inglês

10.1111/j.1749-6632.1993.tb17190.x

1749-6632

Antonella Surbone, Larry Norton,

Breast Cancer Treatment Studies

Annals of the New York Academy of SciencesVolume 698, Issue 1 p. 48-62 Kinetic Concepts in the Treatment of Breast Cancer ANTONELLA SURBONE, Corresponding Author ANTONELLA SURBONE Department of Medicine Memorial Sloan-Kettering Cancer Center New York, New York 10021Antonella Surbone, M.D., Vice-Chairman, Department of Oncology, Santa Chiara Hospital, via Roma 67, 56100 Pisa, Italy.Search for more papers by this authorLARRY NORTON, LARRY NORTON Department of Medicine Memorial Sloan-Kettering Cancer Center New York, New York 10021Search for more papers by this author ANTONELLA SURBONE, Corresponding Author ANTONELLA SURBONE Department of Medicine Memorial Sloan-Kettering Cancer Center New York, New York 10021Antonella Surbone, M.D., Vice-Chairman, Department of Oncology, Santa Chiara Hospital, via Roma 67, 56100 Pisa, Italy.Search for more papers by this authorLARRY NORTON, LARRY NORTON Department of Medicine Memorial Sloan-Kettering Cancer Center New York, New York 10021Search for more papers by this author First published: November 1993 https://doi.org/10.1111/j.1749-6632.1993.tb17190.xCitations: 11AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Norton, L. 1991. Metastatic breast cancer–length and quality of life (editorial). N. Engl. J. Med. 325: 1370–1371. 2 Hryniuk, W. M. 1988. The importance of dose intensity in the outcome of chemotherapy. In Important Advances in Oncology 1988. Vincent T. DeVita, Samuel Hellman & Steven A. Rosenberg, Eds.: 121–141. J. B. Lippincott. Philadelphia , PA . 3 Peters, W. P. 1991. High dose chemotherapy and autologous bone marrow support for breast cancer. In Important Advances in Oncology 1991. V. T. DeVita, S. Hellman & S. A. Rosenberg, Eds.: 135–150. Lippincott. New York , NY . 4 Skipper, H. E., F. M. Schabel, Jr. & W. S. Wilcox. 1964. Experimental evaluation of potential anticancer agents XIII: On the criteria and kinetics associated with “curability” of experimental leukemia. Cancer Chemother. Rep. 35: 1–111. 5 Skipper, H. E. 1986. Laboratory models: The historical perspective. Cancer Treat. Rep. 70: 3–7. 6 Skipper, H. E. 1986. Analyses of multiarmed trials in which animals bearing different burdens of L1210 leukemia cells were treated with two, three, and four drug combinations delivered in different ways with varying dose intensities of each drug and varying average dose intensities. South. Res. Inst. Booklet 7: 42, 87–92. 7 Luria, S. E. & M. Delbruck. 1943. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 28: 491. 8 Law, L. W. 1952. Origin of resistance of leukaemic cells to folic acid antagonists. Nature 169: 628–629. 9 DeVita, V. T., Jr., R. C. Young & G. P. Canellos. 1975. Combination vs. single agent chemotherapy: A review of the basis for selection of drug treatment of cancer. Cancer 35: 98–110. 10 Frei, E., III, E. J. Freireich, E. Gehan, D. Pinkel, J. F. Holland, O. Selawry, F. Haurani, C. L. Spurr, D. M. Hayes, G. W. James, H. Rothberg, D. B. Sodee, R. W. Rundles, L. R. Schroeder, B. Hoogstraten, I. J. Wolman & D. G. Traggis. 1961. Studies of sequential and combination antimetabolite therapy in acute leukemia: 6-Mercaptopurine and methotrexate. Blood 18: 431–454. 11 Greenspan, E. M. 1966. Combination cytotoxic chemotherapy in advanced disseminated breast carcinoma. J. Mt. Sinai Hosp. 33: 1–24. 12 Goldie, J. H. & A. J. Coldman. 1979. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63: 1727–1733. 13 Fidler, I. J. 1978. Tumor heterogeneity and the biology of cancer invasion and metastases. Cancer Res. 38: 2651–2660. 14 Rosen, P. P. & S. Groshen. 1990. Factors influencing survival and prognosis in early breast carcinoma (T1N0M0-T1N1M0): Assessment of 644 patients with median follow-up of 18 years. Surg. Clin. North Am. 70: 937–962. 15 Goldie, J. H. 1987. Scientific basis for adjuvant and primary (neoadjuvant) chemotherapy. Semin. Oncol. 14: 1–7. 16 Goldie, J. H. & A. H. Coldman. 1986. Application of theoretical models to chemotherapy protocol design. Cancer Treat. Rep. 70: 127–131. 17 Kardinal, C. G., M. C. Perry, A. H. Korzun, M. A. Rice, S. Ginsberg & W. C. Wood. 1988. Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy: A subset analysis of CALGB study 8081. Cancer 61: 415–419. 18 Valagussa, P., G. Tancini & G. Bonadonna. 1986. Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy. Cancer 58: 1411–1417. 19 Ludwig Breast Cancer Study Group. 1988. Combination adjuvant chemotherapy for node-positive breast cancer. N. Engl. J. Med. 319: 677–683. 20 Perloff, M., L. Norton, A. Korzun, W. Wood, R. Carey, V. Weinberg & J. F. Holland 1986. Advantage of an adriamycin combination plus halotestin after initial CMFVP for adjuvant therapy of node-positive stage II breast cancer. Proc. Am. Soc. Clin. Oncol. 70: 273. 21 Buzzoni, R., G. Bonadonna, P. Valagussa & M. Zambetti. 1991 Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J. Clin. Oncol. 9: 2134–2140. 22 G. Bonadonna, P. Valagussa, M. Zambetti & R. Buzzoni. 1992. Sequential adriamycin-CMF in the adjuvant treatment of breast cancer with more than three positive axillary nodes. Proc. Am. Soc. Clin. Oncol. 70: 61. 23 Bloom, H., M. Richardson & B. Harris. 1962. Natural history of untreated breast cancer (1804–1933): Comparison of treated and untreated cases according to histological grade of malignancy. Br. Med. J. 2: 213–221. 24 Norton, L. 1988. A Gompertzian model of human breast cancer growth. Cancer Res. 48: 7067–7071. 25 Norton, L. 1989. (Reply to letter to the editor.) Cancer Res. 49: 644. 26 Early Breast Cancer Trialists Collaborative Group. 1992. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 1–15, 71–85. 27 Norton, L. & R. Simon. 1977. Tumor size, sensitivity to therapy, and the design of treatment schedules. Cancer Treat. Rep. 61: 1307–1317. 28 Norton, L. & R. Simon. 1986. The Norton-Simon hypothesis revisited. Cancer Treat. Rep. 70: 163–169. 29 Norton, L. 1985. Implications of kinetic heterogeneity in clinical oncology. Semin. Oncol. 12: 231–249. 30 C. Hudis, D. Lebwohl, J. Crown, T. Gilewski, A. Surbone, T. Hakes, B. Reichman, A. Seidman, M. Harrison, R. Bellettieri, N. Hamilton, T. J. Yao, L. Weiselberg, A. Moore, S. Greenberg & L. Norton. 1992. Feasibility of adjuvant dose-intensive cyclophosphamide with G-CSF after doxorubicin in women with high-risk stage II/III resectable breast cancer. Proc. Am. Soc. Clin. Oncol. 48: 55. 31 Seidman, A. S., L. Norton, B. S. Reichman, J. P. A. Crown, T.-J. Yao, R. Heelan, T. B. Hakes, D. E. Lebwohl, T. A. Gilewski, A. Surbone, V. Currie, C. A. Hums, R. Klecker, C. Jamis-Dow, J. Collins, S. Quinlivan, R. Berkery, F. Toomasi, R. Canetta, J. Fisherman & S. Arbuck. 1993. Preliminary experience with taxol plus recombinant human granulocyte colony stimulating factor in the treatment of metastatic breast cancer. Cancer. In press. 32 W. P. Peters, M. Ross, J. Vredenburgh, B. Meisenberg, G. Rosner, L. Marks, B. Mathias, C. Henderson, D. Hurd, D. Budman, L. Norton & R. B. Weiss. 1992. High-dose alkylating agents and autologous bone marrow support for stage II/III breast cancer including 10 or more axillary lymph nodes. Proc. Am. Soc. Clin. Oncol. 59: 58. 33 Teicher, B. A., S. A. Holden, J. P. Eder, T. W. Brann, S. M. Jones & E. Frei, III. 1989. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. Cancer Res. 49: 5994–5998. 34 Valeriote, F. & L. van Putten 1975. Proliferation-dependent cytotoxicity of anticancer agents: A review. Cancer Res. 35: 2619–2630. 35 Rosso, R., A. Alama, L. Repetto & P. F. Conte. 1990. Timed sequential chemotherapy following ifosfamide-induced kinetic recruitment in refractory ovarian carcinoma. Cancer Chemother. Pharmacol. 26 Suppl.: S43–44. 36 Meyer, J. S., M. U. Prey, D. S. Babcock & R. W. McDivitt. 1986. Breast carcinoma cell kinetics, morphology, stage and host characteristics. A thymidine labeling study. Lab. Invest. 54: 41–51. 37 Frei, E., III, K. Antman, B. Teicher, P. Eder & L. Schnipper. 1989. Bone marrow autotransplantation for solid tumors-prospects. J. Clin. Oncol. 7: 515–526. 38 Jones, R. B., J. F. Holland, S. Bhardwaj, L. Norton, C. Wilfinger & A. Strashun. 1987. A phase I-II study of intensive-dose adriamycin for advanced breast cancer. J. Clin. Oncol. 5: 172–177. 39 Dressler, L. G. 1991. DNA flow cytometry measurements have significant prognostic impact in the node negative breast cancer patient: An intergroup study (INT 0076). In Treatment of Early Stage Breast Cancer: Program and Abstracts: 99–101. NIH Consensus Development Conference, National Cancer Institute and the Office of Medical Applications of Research of the National Institutes of Health, June 18–21, 1991. 40 Silvestrini, R., M. G. Daidone, P. Valagussa, B. Salvadori, D. Rovini, G. Bonadonna 1987. Cell kinetics as a prognostic marker in locally advanced breast cancer. Cancer Treat. Rep. 71: 375–379. 41 Dressler, L. G. & S. A. Bartow. 1989. DNA flow cytometry in solid tumors: Practical aspects and clinical applications. Semin. Diagnostic Pathol. 6: 55–82. 42 Lippman, M. E., J. C. Allegra, E. G. Thompson, R. Simon, A. Barlock, L. Green, K. Hoff, H. Hyido, S. Aitken & R. Warren. 1978. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N. Engl. J. Med. 298: 1223–1228. 43 Hilf, R., M. L. Feldstein, E. D. Savlov, S. Gibson & B. Seneca. 1980. The lack of relationship between estrogen receptor status and response to chemotherapy. Cancer 46: 2729–2800. 44 Kiang, D. T., D. H. Frenning, J. Gay, A. Goldman & B. Kennedy. 1980. Estrogen receptor status and response to chemotherapy in advanced breast cancer. Cancer 46: 2814–2817. 45 Jonat, W., H. Maass, G. Stolzenbach & G. Trams. 1980. Estrogen receptor status and response to polychemotherapy in advance breast cancer. Cancer 46: 2809–2813. 46 Samal, B. A., S. C. Brooks, G. Cummings, L. Franco, E. Hire, S. Martino, A. Singhakowinta & V. Vaitkevicius. 1980. Estrogen receptors and responsiveness of advanced breast cancer to chemotherapy. Cancer 46: 2925–2927. 47 Rubens, R. D. & J. L. Hayward. 1980. Estrogen receptors and response to endocrine therapy and cytotoxic chemotherapy in advanced breast cancer. Cancer 46: 2922–2924. 48 Rosenbaum, C., T. A. Marsland, L. Stolbach et al. 1980. Estrogen receptor status and response to chemotherapy in advanced breast cancer. Cancer 46: 2919–2921. 49 Swain, S. M., R. A. Sorace, C. S. Bagley, D. N. Danforth, Jr., J. Bader, M. N. Wesley, S. M. Steinberg & M. E. Lippman. 1987. Neoadjuvant chemotherapy in the combined modality approach of locally advanced non-metastatic breast cancer. Cancer Res. 47: 3889–3894. 50 Conte, P. F., A. Alama, G. Bertelli, G. Canavese, F. Carnino, A. Catturich, E. Di Marco, G. Gardin, A. Jacomuzzi, C. Monzeglio, C. Mossetti, A. Nicolin, P. Pronzato & R. Rosso. 1987. Chemotherapy with estrogenic recruitment and surgery in locally advanced breast cancer: Clinical and cytokinetic results. Int. J. Cancer 40: 490–494. 51 Conte, P. F., P. Pronzato, A. Rubagotti, A. Alama, D. Amadori, R. Demicheli, G. Gardin, P. Gentilini, A. Jacomuzzi, R. Lionetto, C. Monzeglio, A. Nicolin, R. Rosso, P. Sismondi, M. Sussion & L. Santi. 1987. Conventional vs. cytokinetic polychemotherapy with estrogenic recruitment in metastatic breast cancer: Results of a randomized cooperative trial. J. Clin. Oncol. 5: 339–347. 52 Norton, L. 1990. Biology of residual breast cancer after therapy: A kinetic interpretation. In Effects of Therapy on Biology and Kinetics of the Residual Tumor, Part A: Pre-Clinical Aspects. J. Ragaz, L. Simpson-Herren, M. E. Lippman & B. Fisher, Eds.: 109–132. Wiley-Liss. New York , NY . 53 Lippman, M. E., R. B. Dickson, S. Bates, C. Knabbe, K. Huff, S. Swain, M. McManaway, D. Bronzert, A. Kasid & E. P. Gelman. 1986. Autocrine and paracrine growth regulation of human breast cancer. Breast Cancer Res. Treat. 7: 59–70. 54 Rosen, N., D. Yee, M. E. Lippman, S. Paik & K. J. Cullen. 1991. Insulin-like growth factors in human breast cancer. Breast Cancer Res. Treat. 18 Suppl. 1: s55–62. 55 Fidler, I. J. 1991. 7th Jan Waldenstrom Lecture. The biology of human cancer metastasis. Acta Oncol. 30: 668–675. 56 Lippman, M. E. 1987. Hormonal stimulation and chemotherapy for breast cancer (editorial). J. Clin. Oncol. 5: 331–332. 57 Koury, M. J. & M. C. Bondurant. 1990. Erythropoietin retards DNA breakdown and prevents programmed death in erythoid progenitor cells. Science 248: 378–381. 58 Williams, G. T., C. A. Smith, E. Spooncer, T. M. Dexter & D. R. Taylor. 1990. Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature 343: 76–79. 59 Barry, M. A., C. A. Behnke & A. Eastman. 1990. Activation of programmed cell death (apoptosis) by cisplain, other anticancer drugs, toxins and gyperthermia. Biochem. Pharmacol. 40: 2353–2362. 60 Bontenbal, M., A. M. Sieuwerts, J. G. M. Klijn, H. A. Peter, H. L. J. M. Krijnen, P. Sonneveld & J. A. Foekens. 1989. Effect of hormonal manipulation and doxorubicin administration on cell cycle kinetics of human breast cancer cells. Br. J. Cancer 60: 688–692. 61 Teicher, B. A., T. S. Herman, S. A. Holden, Y. Wang, M. R. Pfeffer, J. W. Crawford & E. Frei, III 1990. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 247: 1457–1461. 62 Marks, P. A. & R. A. Rifkind. 1991. Differentiating agents in cancer therapy. Cancer Chemother. Biol. Response Modif. 12: 291–305. 63 Norton, L., J. Baselga, H. Masui, J. Hyman, R. Kumar & J. Mendelsohn. 1991. Growth factor perturbation: A therapeutically exploitable mechanism for chemotherapy action. Proc. Am. Soc. Clin. Oncol. 208: 84. 64 Baselga, J., L. Norton, W. Miller, H. Masui & J. Mendelsohn. 1992. Synergistic antitumor effects of adriamycin and anti-epidermal growth factor receptor monoclonal antibodies. Proc. Am. Soc. Clin. Oncol. 238: 104. 65 Zuckiet, G. & T. R. Tritton. 1983. Adriamycin causes up-regulation of epidermal growth factor receptors in actively growing cells. Exp. Cell Res. 148: 155–161. 66 Aboud-Pirak, E., E. Hurwitz, M. E. Pirak, F. Fellot, J. Schlessinger & M. Sela. 1988. Efficacy of antibody to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J. Natl. Cancer Inst. 80: 1605–1611. 67 Pegram, M. D., R. J. Pietras & D. J. Slamon. 1992. Monoclonal antibody to HER-2/neu gene product potentiates cytotoxicity of carboplatin and doxorubicin in human breast tumor cells. Am. Assoc. Cancer Res. 2639. 68 Pietras, R. J., S. Scates, S. B. Howell & D. J. Slamon. 1992. Monoclonal antibody to HER-2/neu receptor modulates DNA repair and platinum sensitivity in human breast and ovarian carcinoma cells. Am. Assoc. Cancer Res. 39: 547. Citing Literature Volume698, Issue1Breast Cancer: From Biology to Therapy–Pisa Symposia in OncologyNovember 1993Pages 48-62 ReferencesRelatedInformation